Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

Benjamin Rolland (1, 2, 3) , Benoit Trojak (4, 5) , Mikail Nourredine (1) , Jérôme Bachellier (6) , Mathieu Chappuy (1, 2) , Patrick Bendimerad , Margaux Kosim (7) , Peter Hjelmström , Fadi Meroueh (8, 9) , Philippe Nubukpo (10) , Georges Brousse (11, 12)

1 Centre Hospitalier le Vinatier [Bron]
2 HCL - Hospices Civils de Lyon
3 CRNL - Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
4 CAPS - Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093]
5 UFR Sciences du Sport (STAPS) (Université de Bourgogne)
6 Hôpital Bretonneau
7 CHU Pitié-Salpêtrière [AP-HP]
8 UCSA - Unité Consultations et de Soins Ambulatoires [Nîmes]
9 CHU - Hôpital Lapeyronie [Montpellier]
10 NET - Neuroépidémiologie Tropicale
11 CHU Clermont-Ferrand
12 NPsy-Sydo - Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux

Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France. Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-related features (e.g., type of OAT and prescriber, dosing, or duration of treatment), OAT representations, and personal objectives of treatment. Results: The median interest in XR-BUP was 7 (interquartile range: 3-9) out of 10. The participants who were 'more interested' (i.e. those scoring ≥7) showed no substantial difference in sociodemographic characteristics, relative to the 'less interested' participants. However, they more frequently reported forgetting to take their OAT (OR = 1.81; CI95 % = 1.06-3.10) or reported experiencing situations where taking their OAT was impractical (aOR = 1.69; CI95 % = 1.05-2.73). Their treatment objective was more focused on stopping illicit drugs (aOR = 1.67; 95 %CI = 1.02-2.70), reducing health risks (aOR = 3.57; 95 %CI = 1.67-7.69) and craving (aOR = 2.38; 95 %CI = 1.39-4.02) or improving family (aOR = 1.81; 95 %CI = 1.03-3.13) or professional (aOR = 2.22; 95 %CI = 1.43-3.85) recovery. Conclusions: In France, where the access to OAT is relatively unrestricted, the majority of participants were interested in XR-BUP formulations. Being interested was associated with treatment objectives focused on abstinence and recovery, and with experiencing constraints in taking a daily oral OAT.

Mots clés: Buprenorphine; Extended-release; France; Patients' preference; Survey

Domaines: Sciences du Vivant [q-bio]

Benjamin Rolland, Benoit Trojak, Mikail Nourredine, Jérôme Bachellier, Mathieu Chappuy, et al.. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Drug and Alcohol Dependence, 2021, 220, pp.108492. ⟨10.1016/j.drugalcdep.2020.108492⟩. ⟨hal-03280782⟩